The group’s principal activities include to manufacturing and marketing bio-pharmaceutical products. The group products include Influenza, Epidemic Hemorrhagic Fever, Epidemic Japanese Encephalitis, and W135 Meningococcal Polysaccharide. Customers of the group include local hospitals, clinics, and pension fund health programs. The group operates from China and the United States. Of the total revenue in the year 2006 China accounted for $1,202,763.
